Fig. 3From: Systemic and central nervous system metabolic alterations in Alzheimer’s diseaseSystemic and central nervous system alterations in products of tryptophan breakdown in AD. Direction of metabolite alterations in AD patients versus control in plasma (PL) and CSF; ↑ higher concentrations in AD vs control, ↓ lower concentrations in AD vs control, “-“ indicates “not detected” or below limit of quantification, * statistically significant higher or lower concentrations in AD vs control P < 0.05 (T-test)Back to article page